DISCOUNT ZERTIFIKAT - ARGENX SE Share Price

Certificat

DE000ME7KTF2

Delayed Börse Stuttgart 06:04:37 27/06/2024 pm IST
274.8 EUR +0.42% Intraday chart for DISCOUNT ZERTIFIKAT - ARGENX SE
Current month+2.38%
1 month+3.48%
Date Price Change
27/24/27 274.8 +0.42%
26/24/26 273.6 +0.32%
25/24/25 272.7 +0.07%
24/24/24 272.6 +1.26%
21/24/21 269.2 -0.11%

Delayed Quote Börse Stuttgart

Last update June 27, 2024 at 06:04 pm IST

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying ARGENX SE
Issuer Morgan Stanley
WKN ME7KTF
ISINDE000ME7KTF2
Date issued 25/01/2024
Cap 275
Last trading day 20/09/2024
Maturity 20/09/2024 (85 Days)
Parity 1 : 1
Emission price 260.9
Emission volume N/A
Payment day 27/09/2024
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 34.16 %
Sideways yield 0.0437 %
Sideways yield pa 0.1875 %
Outperformance point 417.7
Break even 272.71 €
Highest since issue 274.8
Lowest since issue 257.5
Spread 0.24
Spread %0.09%
Distance Cap 140.5
Distance Cap %+33.81%
Max. earning 0.12
Max. earning % 0.0437 %

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Sector
-
More about the company

Ratings for argenx SE

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: argenx SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
419.7 EUR
Average target price
451.6 EUR
Spread / Average Target
+7.61%
Consensus